The FDA on July 30, 2019 approved NUBEQA® for non-metastatic Castration-Resistant Prostate Cancer (CRPC). NUBEQA® is a product of Bayer HealthCare Pharmaceuticals Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement